Adaptive Biotechnologies
ADPT
250 hedge funds and large institutions have $6.75B invested in Adaptive Biotechnologies in 2020 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 81 increasing their positions, 81 reducing their positions, and 15 closing their positions.
440% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $4.4M
307% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 15
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
25% more capital invested
Capital invested by funds: $5.41B → $6.75B (+$1.34B)
21% more funds holding
Funds holding: 206 → 250 (+44)
1.42% more ownership
Funds ownership: 82.03% → 83.45% (+1.4%)
0% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 81
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$109M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.7M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$34.1M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$180M |
| 2 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$26.9M |
| 3 |
SIG
Senator Investment Group
New York
|
-$25.8M |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$24.2M |
| 5 |
Goldman Sachs
New York
|
-$20.2M |
ADPT Hedge Fund Activity: Q4 2020 in Review
250 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2020, worth a combined $6.75B — up 25% from $5.41B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new ADPT positions and 15 closed out — a net gain of 46 holders — while 81 added to existing stakes and 81 trimmed.
The largest buyer was Vanguard Group, adding an estimated $134M. The largest seller was Viking Global Investors, cutting an estimated $180M.
- 250 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2020, up from 206 in Q3 2020.
- Funds reported $6.75B of Adaptive Biotechnologies stock for Q4 2020, up 25% quarter-over-quarter.
- 61 funds opened new Adaptive Biotechnologies positions in Q4 2020 and 15 closed out, a net change of +46 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2020 was Vanguard Group, an estimated $134M added.
- The largest Adaptive Biotechnologies seller in Q4 2020 was Viking Global Investors, an estimated $180M sold.
Based on aggregated 13F filings for Q4 2020.